Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 2/20 | 0.30 |
| ▸ | CTSS | P25774 | 1/20 | 0.30 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3610450 | 0.81 | KEAP1 (0.34) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL16742415 | 0.79 | HDAC3 (0.36) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL10512876 | 0.77 | DGAT1 (0.36) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL11241248 | 0.76 | EPHX2 (0.35) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL14945698 | 0.75 | DGAT1 (0.34) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL485846 | 0.75 | — | — | |
| SCHEMBL23709990 | 0.74 | CYP2D6 (0.39) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL944872 | 0.74 | EPHX2 (0.39) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL2133709 | 0.74 | EPHX2 (0.39) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL17643549 | 0.73 | CYP2D6 (0.37) | CYP2D6HDAC3HDAC1HDAC2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4175943-B1 | DUAL-FUNCTIONAL COMPOUNDS AND METHODS OF USE | BIOFRONT THERAPEUTICS BEIJING CO LTD (CN) | 2026-02-11 | — | — | EP | disclosed |
| US-11987556-B2 | Dual-functional compounds and methods of use | BIOFRONT THERAPEUTICS (BEIJING) CO., LTD. (CN) | 2024-05-21 | — | — | US | disclosed |
| CN-113767104-B | Bifunctional compounds and methods of use thereof | 百放英库医药科技(北京)有限公司 | 2023-08-22 | — | — | CN | disclosed |
| US-20230174482-A1 | DUAL-FUNCTIONAL COMPOUNDS AND METHODS OF USE | BIOFRONT THERAPEUTICS (BEIJING) CO., LTD. (CN) | 2023-06-08 | — | — | US | disclosed |
| US-20230151024-A1 | STING AGONISTIC COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2023-05-18 | — | — | US | disclosed |
| US-20230141284-A1 | CANCER THERAPEUTIC METHOD | ONO PHARMACEUTICAL CO., LTD. (JP) | 2023-05-11 | — | — | US | disclosed |
| EP-4175943-A1 | DUAL-FUNCTIONAL COMPOUNDS AND METHODS OF USE | Biofront Therapeutics (Beijing) Co., Ltd. (CN) | 2023-05-10 | — | — | EP | disclosed |
| US-20230115871-A1 | A CONJUGATE OF A CYTOTOXIC AGENT TO A CELL BINDING MOLECULE WITH BRANCHED LINKERS | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2023-04-13 | — | — | US | disclosed |
| US-20230115871-A1 | A CONJUGATE OF A CYTOTOXIC AGENT TO A CELL BINDING MOLECULE WITH BRANCHED LINKERS | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2023-04-13 | — | — | US | disclosed |
| EP-4134098-A1 | METHOD OF CANCER THERAPY | ONO Pharmaceutical Co., Ltd. (JP) | 2023-02-15 | — | — | EP | disclosed |
| US-20130123231-A1 | ACC INHIBITORS AND USES THEREOF | Nimbus Apollo, Inc. (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130012706-A1 | Methods and Intermediates for the Synthesis of 4-oxo-3,4-dihydro-imidazo[5,1-d][1,2,3,5]tetrazines | PHARMINOX LIMITED (GB) | 2013-01-10 | — | — | US | disclosed |
| WO-2012115286-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PRISM BIOLAB CORPORATION (JP) | 2012-08-30 | — | — | WO | disclosed |
| US-20100286088-A1 | 3-Substituted-4-Oxo-3,4-Dihydro-Imidazo[5,1-d][1,2,3,5-Tetrazine-8-Carboxylic Acid Amides and Their Use | PHARMINOX LIMITED (GB) | 2010-11-11 | — | — | US | disclosed |
| US-20100286088-A1 | 3-Substituted-4-Oxo-3,4-Dihydro-Imidazo[5,1-d][1,2,3,5-Tetrazine-8-Carboxylic Acid Amides and Their Use | PHARMINOX LIMITED (GB) | 2010-11-11 | — | — | US | disclosed |
| US-20100286088-A1 | 3-Substituted-4-Oxo-3,4-Dihydro-Imidazo[5,1-d][1,2,3,5-Tetrazine-8-Carboxylic Acid Amides and Their Use | PHARMINOX LIMITED (GB) | 2010-11-11 | — | — | US | disclosed |
| EP-2229393-A2 | 3-SUBSTITUTED-4-OXO-3,4-DIHYDRO-IMIDAZO-[5,1-D][1,2,3,5]-TETRAZINE-8-CARBOXYLIC ACID AMIDES AS ANTICANCER AGENTS | PHARMONIX LIMITED (GB) | 2010-09-22 | — | — | EP | disclosed |
| WO-2009077741-A2 | 3-SUBSTITUTED-4-OXO-3,4-DIHYDRO-IMIDAZO-[5,1-D][1,2,3,5-TETRAZINE-8-CARBOXYLIC ACID AMIDES AND THEIR USE | PHARMINOX LIMITED (GB) | 2009-06-25 | — | — | WO | disclosed |
| WO-2009077741-A2 | 3-SUBSTITUTED-4-OXO-3,4-DIHYDRO-IMIDAZO-[5,1-D][1,2,3,5-TETRAZINE-8-CARBOXYLIC ACID AMIDES AND THEIR USE | PHARMINOX LIMITED (GB) | 2009-06-25 | — | — | WO | disclosed |
| US-4692461-A | PLANT PROTECTION | BAYER AKTIENGESELLSCHAFT (DE) | 1987-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230141284-A1 | CANCER THERAPEUTIC METHOD | STING1, CGAS, IFNAR1 | CYP2D6 2634/4885HDAC3 4809/4885HDAC1 4790/4885 |
| US-20130012706-A1 | Methods and Intermediates for the Synthesis of 4-oxo-3,4-dihydro-imidazo[5,1-d][1,2,3,5]tetrazines | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CA6, TALDO1 | CYP2D6 35/4885HDAC3 236/4885HDAC1 203/4885 |
| US-20230115871-A1 | A CONJUGATE OF A CYTOTOXIC AGENT TO A CELL BINDING MOLECULE WITH BRANCHED LINKERS | CD2BP2, EPCAM, CD74 | CYP2D6 3809/4885HDAC3 3799/4885HDAC1 3630/4885 |
| US-20100286088-A1 | 3-Substituted-4-Oxo-3,4-Dihydro-Imidazo[5,1-d][1,2,3,5-Tetrazine-8-Carboxylic Acid Amides and Their Use | MKI67, CCNI, CDK4 | CYP2D6 505/4885HDAC3 6/4885HDAC1 9/4885 |
| US-20230174482-A1 | DUAL-FUNCTIONAL COMPOUNDS AND METHODS OF USE | PDE1A, PDE3B, PDE1B | CYP2D6 488/4885HDAC3 2133/4885HDAC1 619/4885 |
| US-20230151024-A1 | STING AGONISTIC COMPOUND | STING1, CGAS, TLR1 | CYP2D6 4253/4885HDAC3 4791/4885HDAC1 4187/4885 |
| US-20130123231-A1 | ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, ACAT2 | CYP2D6 2306/4885HDAC3 318/4885HDAC1 415/4885 |
| US-11987556-B2 | Dual-functional compounds and methods of use | PDE1A, PDE3B, PDE1B | CYP2D6 488/4885HDAC3 2133/4885HDAC1 619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.